SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene ...

A large-scale study has identified dozens of blood proteins linked to prostate cancer risk, some shared across populations, some unique to specific groups. Published in Nature Communications, the ...

Hormone therapy initiation depends on disease extent; some agents avoid testosterone flare, allowing ADT without Casodex in certain cases. Active surveillance is increasingly chosen for favorable ...

Add Yahoo as a preferred source to see more of our stories on Google. Researchers say they've developed a urine test that could answer whether prostate cancer is ...

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...

NEW YORK (Reuters Health) - Hypoxia, or reduced oxygen levels, in prostate tumors significantly predicts a poor long-term biochemical outcome, regardless of other prognostic factors, such as tumor ...

How unfavorable is AUA unfavorable intermediate-risk prostate cancer? Results from a large, institutional cohort. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium.

Los Angeles, Calif. – Testosterone therapy does not cause adverse effects on the prostate in older men with hypogonadism, commonly known as low testosterone or low T, according to a clinical trial ...